Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE-NK: Immunotherapy vs Chemotherapy Induction in Advanced Extranodal NK/T-Cell Lymphoma
NCT07678229Phase 3Recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab, anlotinib in Extranodal NK/T-cell lymphoma (ENKTL). Started Aug 2026; status: recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT07678229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07678229.